SCHEMBL10123574

SCHEMBL10123574

C=C(NNc1ccc(-c2ccccc2)cc1)NC(C)(C(F)(F)F)C(F)(F)F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 0.40
MAPT P10636 3/20 0.40
KDM4E B2RXH2 2/20 0.40
TP53 P04637 1/20 0.40
THRB P10828 1/20 0.40
RECQL P46063 1/20 0.40
PLEC Q15149 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
ALDH1A1 P00352 1/20 0.37
LMNA P02545 2/20 0.35
HTT P42858 1/20 0.35
CYP3A4 P08684 1/20 0.34
ALOX5 P09917 1/20 0.34
TSHR P16473 1/20 0.34
HDAC1 Q13547 2/20 0.34
HDAC7 Q8WUI4 2/20 0.34
HDAC8 Q9BY41 2/20 0.34
HDAC6 Q9UBN7 2/20 0.34
KIF11 P52732 1/20 0.33
HDAC3 O15379 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10123569 0.91 ALDH1A1 (0.45) GAAMAPTKDM4ETP53THRB
SCHEMBL10123578 0.82 GAA (0.42) GAAMAPTKDM4ETP53THRB
SCHEMBL10123572 0.82 KDM4E (0.42) GAAMAPTKDM4ETP53THRB
SCHEMBL13993345 0.78 KDM4E (0.42) GAAMAPTKDM4ETP53THRB
SCHEMBL10123498 0.78 MAPT (0.46) GAAMAPTKDM4ETP53THRB
SCHEMBL10123534 0.75 GAA (0.43) GAAMAPTKDM4ETP53THRB
SCHEMBL10123461 0.74 MEN1 (0.38) GAAMAPTKDM4ETP53THRB
SCHEMBL10123568 0.73 PDK1 (0.44) GAAMAPTKDM4ETP53THRB
SCHEMBL10123533 0.71 PDK1 (0.50) MAPTALDH1A1LMNAHTTPDK1
SCHEMBL29042738 0.62 ALDH1A1 (0.71) MAPTKDM4EL3MBTL1ALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012060820-A1 SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES SIGA TECHNOLOGIES, INC. (US) 2012-05-10 WO disclosed